{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:58:24Z","timestamp":1781567904703,"version":"3.54.5"},"reference-count":163,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"vor","delay-in-days":349,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.det.2015.05.012","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T14:00:23Z","timestamp":1439906423000},"page":"787-805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Catherine G.","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Poligone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","article-title":"Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)","volume":"64","author":"Olsen","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and sezary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","article-title":"Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma","volume":"10","author":"Redman","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.det.2015.05.012_bib5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2133.2004.05712.x","article-title":"Treatment of advanced mycosis fungoides\/Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy","volume":"150","author":"Quaglino","year":"2004","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.det.2015.05.012_bib7","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","article-title":"Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"12","author":"Foss","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib8","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2133.2001.04191.x","article-title":"A\u00a0trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma","volume":"144","author":"Scarisbrick","year":"2001","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/oxfordjournals.annonc.a058693","article-title":"High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias","volume":"5","author":"Betticher","year":"1994","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V84.3.733.733","article-title":"2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders","volume":"84","author":"O'Brien","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","article-title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","volume":"87","author":"Kuzel","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.det.2015.05.012_bib12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/archderm.135.10.1279","article-title":"Low-dose 2-chlorodeoxyadenosine for the treatment of mycosis fungoides","volume":"135","author":"Trautinger","year":"1999","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib13","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0190-9622(88)70224-8","article-title":"Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin)","volume":"19","author":"Dang-Vu","year":"1988","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6 Pt 1","key":"10.1016\/j.det.2015.05.012_bib17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0190-9622(97)80279-4","article-title":"Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma","volume":"36","author":"Greiner","year":"1997","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2015.05.012_bib18","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1023\/A:1008377724139","article-title":"Pentostatin in T-cell malignancies\u2013a phase II trial of the EORTC. Leukemia Cooperative Group","volume":"10","author":"Ho","year":"1999","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.det.2015.05.012_bib19","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.det.2015.05.012_bib20","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/bjh.12320","article-title":"Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides\/Sezary syndrome","volume":"162","author":"Calderon Cabrera","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archderm.1995.01690150071014","article-title":"Treatment of advanced mycosis fungoides and Sezary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue","volume":"131","author":"Schappell","year":"1995","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.det.2015.05.012_bib24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.012_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.me.21.020170.000423","article-title":"Topical antimetabolites","volume":"21","author":"Zackheim","year":"1970","journal-title":"Annu Rev Med"},{"issue":"8","key":"10.1016\/j.det.2015.05.012_bib26","first-page":"1017","article-title":"Six patients with early-stage cutaneous T-cell lymphoma successfully treated with topical 5-fluorouracil","volume":"9","author":"Kannangara","year":"2010","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"Suppl 5","key":"10.1016\/j.det.2015.05.012_bib27","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.det.2015.05.012_bib28","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.det.2015.05.012_bib29","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2133.2009.09230.x","article-title":"Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases","volume":"161","author":"Jidar","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib32","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.3816\/CLM.2009.n.079","article-title":"Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides","volume":"9","author":"Buhl","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"10","key":"10.1016\/j.det.2015.05.012_bib33","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/bjc.2013.616","article-title":"Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma","volume":"109","author":"Illidge","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000324581","article-title":"Gemcitabine monotherapy associated with posterior reversible encephalopathy syndrome","volume":"4","author":"Marrone","year":"2011","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.det.2015.05.012_bib35","first-page":"656","article-title":"Nitrogen mustards in the treatment of neoplastic disease; official statement","volume":"131","author":"Rhoads","year":"1946","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.det.2015.05.012_bib36","first-page":"1","article-title":"Nitrogen mustards in the treatment of neoplastic disease","volume":"4","author":"Karnofsky","year":"1950","journal-title":"Adv Intern Med"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib37","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1097-0142(197511)36:5<1613::AID-CNCR2820360513>3.0.CO;2-0","article-title":"Frequent low doses of intravenous mechlorethamine for late-stage mycosis fungoides lymphoma","volume":"36","author":"Van Scott","year":"1975","journal-title":"Cancer"},{"issue":"7127","key":"10.1016\/j.det.2015.05.012_bib38","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(60)90618-8","article-title":"Chlorambucil in erythrodermia","volume":"275","author":"Lib\u00e1nsk\u00fd","year":"1960","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0002-9343(73)90168-X","article-title":"Erythroderma with atypical lymphocytes (S\u00e9zary syndrome)","volume":"55","author":"Winkelmann","year":"1973","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2230.1983.tb01807.x","article-title":"Mycosis fungoides: progression towards Sezary syndrome reversed with chlorambucil","volume":"8","author":"Holmes","year":"1983","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib41","first-page":"60","article-title":"Chlorambucil in mycosis fungoides. Report of a case of successful treatment","volume":"48","author":"Mante","year":"1968","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2133.1979.tb06201.x","article-title":"Sezary's syndrome: a clinical evaluation of eight patients","volume":"100","author":"Hamminga","year":"1979","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2133.2000.03601.x","article-title":"Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy","volume":"143","author":"Coors","year":"2000","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib44","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0190-9622(84)80323-0","article-title":"The treatment of Sezary syndrome","volume":"10","author":"Winkelmann","year":"1984","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2015.05.012_bib45","first-page":"590","article-title":"Treatment of Sezary syndrome","volume":"49","author":"Winkelmann","year":"1974","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib46","first-page":"73","article-title":"Intermittent leukapheresis: an adjunct to low-dose chemotherapy for Sezary syndrome","volume":"69","author":"McEvoy","year":"1989","journal-title":"Acta Derm Venereol"},{"issue":"19","key":"10.1016\/j.det.2015.05.012_bib47","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/jnci\/86.19.1450","article-title":"Risk of Leukemia Following Treatment for Non-Hodgkin's Lymphoma","volume":"86","author":"Travis","year":"1994","journal-title":"Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.det.2015.05.012_bib48","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","article-title":"Risk of second malignancy after non-hodgkin's lymphoma: a British cohort study","volume":"24","author":"Mudie","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.det.2015.05.012_bib49","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-0560.2007.00931.x","article-title":"Transformation of cutaneous gamma\/delta T-cell lymphoma following 15 years of indolent behavior","volume":"35","author":"Hosler","year":"2008","journal-title":"J\u00a0Cutan Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.det.2015.05.012_bib50","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","article-title":"Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma","volume":"14","author":"Zelenetz","year":"2003","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.det.2015.05.012_bib52","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL Study Group","volume":"90","author":"Bergmann","year":"2005","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.det.2015.05.012_bib53","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy","volume":"90","author":"Knop","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"Ponisch","year":"2006","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.det.2015.05.012_bib55","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.cad.0000175587.31940.19","volume":"16","author":"von Minckwitz","year":"2005","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib56","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.det.2015.05.012_bib57","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.det.2015.05.012_bib59","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00277-013-1746-9","article-title":"Bendamustine salvage therapy for T cell neoplasms","volume":"92","author":"Zaja","year":"2013","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib60","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3109\/10428194.2012.739285","article-title":"Bendamustine can severely impair T-cell immunity against cytomegalovirus","volume":"54","author":"Hosoda","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.det.2015.05.012_bib61","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archderm.1960.01580050067008","article-title":"The treatment of mycosis fungoides with a new agent, cyclophosphamide (Cytoxan)","volume":"82","author":"Abele","year":"1960","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/archderm.101.5.611b","article-title":"Mycosis fungoides successfully treated with cyclophosphamide (Cytoxan)","volume":"101","author":"Auerbach","year":"1970","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2133.1968.tb11906.x","article-title":"Treatment of mycosis fungoides with cyclophosphamide and chlorpromazine","volume":"80","author":"Maguire","year":"1968","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib64","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/1097-0142(197003)25:3<715::AID-CNCR2820250332>3.0.CO;2-9","article-title":"Effect of large intermittent intravenous doses of cyclophosphamide in lymphoma","volume":"25","author":"Mendelson","year":"1970","journal-title":"Cancer"},{"key":"10.1016\/j.det.2015.05.012_bib65","first-page":"616","article-title":"Follow-up case mycosis fungoides treated with cyclophosphamide (cytoxan)","volume":"89","author":"Suter","year":"1964","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.012_bib66","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/archderm.1962.01590040063008","article-title":"Treatment of mycosis fungoides with cyclophosphamide","volume":"85","author":"Van Scott","year":"1962","journal-title":"Arch Dermatol"},{"issue":"25","key":"10.1016\/j.det.2015.05.012_bib67","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"10.1016\/j.det.2015.05.012_bib68","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and s\u00e9zary syndrome: a retrospective analysis of the lymphoma working party of the european group for blood and marrow transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib69","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.clml.2014.09.013","article-title":"Long-Term complete responses to combination therapies and allogeneic stem cell transplants in patients with Sezary Syndrome","volume":"15","author":"Polansky","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib70","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-3164.2009.00793.x","article-title":"Canine cutaneous epitheliotropic T-cell lymphoma: a review of 30 cases","volume":"21","author":"Fontaine","year":"2010","journal-title":"Vet Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib71","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1638\/2007-0132.1","article-title":"Chemotherapy and radiotherapy for treatment of cutaneous lymphoma in a ground cuscus (Phalanger gymnotis)","volume":"39","author":"Goodnight","year":"2008","journal-title":"J\u00a0Zoo Wildl Med"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1638\/2013-0217R.1","article-title":"Cutaneous T-cell lymphoma in two captive Tasmanian devils (Sarcophilus harrisii)","volume":"45","author":"Scheelings","year":"2014","journal-title":"J\u00a0Zoo Wildl Med"},{"issue":"7","key":"10.1016\/j.det.2015.05.012_bib73","first-page":"1231","article-title":"[Topical application of ACNU for the treatment of mycosis fungoides]","volume":"9","author":"Jimbow","year":"1982","journal-title":"Gan To Kagaku Ryoho"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)","volume":"65","author":"Newlands","year":"1992","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.det.2015.05.012_bib75","first-page":"1283","article-title":"Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma","volume":"90","author":"Tani","year":"2005","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.det.2015.05.012_bib76","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1158\/1078-0432.CCR-11-0556","article-title":"Multicenter phase II trial of temozolomide in mycosis fungoides\/sezary syndrome: correlation with O(6)-methylguanine-DNA methyltransferase and mismatch repair proteins","volume":"17","author":"Querfeld","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.det.2015.05.012_bib77","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.thj.6200570","article-title":"ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients","volume":"5","author":"Mebazaa","year":"2005","journal-title":"Hematol J"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib78","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.det.2015.05.012_bib79","series-title":"Hematology: basic principles and practice","author":"Hoffman","year":"2013"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib80","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1568011013354723","article-title":"Anthracyclines: selected new developments","volume":"1","author":"Binaschi","year":"2001","journal-title":"Curr Med Chem Anticancer Agents"},{"issue":"Suppl A","key":"10.1016\/j.det.2015.05.012_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0305-7372(02)80003-2","article-title":"Clinical uses of pegylated pharmaceuticals in oncology","volume":"28","author":"Crawford","year":"2002","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.det.2015.05.012_bib82","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A\u00a0comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.det.2015.05.012_bib83","first-page":"751","article-title":"Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl)","volume":"15","author":"Working","year":"1996","journal-title":"Hum Exp Toxicol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib84","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/1097-0142(197705)39:5<1967::AID-CNCR2820390509>3.0.CO;2-2","article-title":"Adriamycin therapy in advanced mycosis fungoides","volume":"39","author":"Levi","year":"1977","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib85","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib86","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2133.2005.06682.x","article-title":"Pegylated liposomal doxorubicin in stage IVB mycosis fungoides","volume":"153","author":"Di Lorenzo","year":"2005","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib87","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3324\/haematol.10879","article-title":"Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas","volume":"92","author":"Pulini","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib88","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"issue":"33","key":"10.1016\/j.det.2015.05.012_bib89","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib90","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/annonc\/mdt480","article-title":"Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma","volume":"25","author":"Straus","year":"2014","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.det.2015.05.012_bib91","first-page":"1","article-title":"Anthracyclines in the treatment of cancer. An overview","volume":"54","author":"Hortobagyi","year":"1997","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00432-002-0403-9","article-title":"Liposomal daunorubicin in tumor stage cutaneous T-cell lymphoma: report of three cases","volume":"129","author":"Wollina","year":"2003","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.det.2015.05.012_bib93","first-page":"95","article-title":"Mycosis fungoides: case report and literature review. clinical medicine insights","volume":"7","author":"Akinbami","year":"2014","journal-title":"Case Rep"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib94","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3892\/ol.2012.973","article-title":"CD8(+) mycosis fungoides with esophageal involvement: a case report","volume":"5","author":"Ishida","year":"2013","journal-title":"Oncol Lett"},{"issue":"8","key":"10.1016\/j.det.2015.05.012_bib95","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1995-7645(12)60138-2","article-title":"A\u00a0case of advanced mycosis fungoides with comprehensive skin and visceral organs metastasis: sensitive to chemical and biological therapy","volume":"5","author":"Liu","year":"2012","journal-title":"Asian Pac J Trop Med"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib96","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000246116","article-title":"Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma","volume":"194","author":"Fierro","year":"1997","journal-title":"Dermatology"},{"issue":"7898","key":"10.1016\/j.det.2015.05.012_bib97","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(75)91128-9","article-title":"Letter: Epipodophyllotoxin in mycosis fungoides","volume":"1","author":"Jacobs","year":"1975","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.det.2015.05.012_bib98","first-page":"1286","article-title":"Letter: Chemotherapy of mycosis fungoides","volume":"49","author":"Jacobs","year":"1975","journal-title":"S\u00a0Afr Med J"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib99","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2340\/00015555598487","article-title":"Epipodophyllotoxin (VP-16-213) in mycosis fungoides: a report from the Scandinavian mycosis fungoides study group","volume":"59","author":"Molin","year":"1979","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.det.2015.05.012_bib100","first-page":"1013","article-title":"A\u00a0case of mycosis fungoides with pulmonary involvement: effect of etoposide and prednisolone","volume":"33","author":"Nasuhara","year":"1995","journal-title":"Nihon Kyobu Shikkan Gakkai Zasshi"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2230.2004.01373.x","article-title":"An elderly patient with mycosis fungoides successfully treated with chronic low-dose oral etoposide therapy","volume":"29","author":"Onozuka","year":"2004","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib102","first-page":"399","article-title":"Complication of topoisomerase II inhibitor-related acute promyelocytic leukemia with t(1;10) (q21;q26) in a patient with Sezary syndrome","volume":"47","author":"Miyoshi","year":"2006","journal-title":"Rinsho Ketsueki"},{"issue":"9","key":"10.1016\/j.det.2015.05.012_bib103","first-page":"750","article-title":"Sezary syndrome showing a stable clinical course for more than four years after oral administration of etoposide and methotrexate","volume":"41","author":"Hirayama","year":"2000","journal-title":"Rinsho Ketsueki"},{"issue":"8780","key":"10.1016\/j.det.2015.05.012_bib104","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/0140-6736(91)92779-2","article-title":"Epipodophyllotoxin-related acute myeloid leukaemia","volume":"338","author":"Pui","year":"1991","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.det.2015.05.012_bib105","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM199112123252402","article-title":"Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia","volume":"325","author":"Pui","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib106","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0889-8588(03)00109-6","article-title":"Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2","volume":"17","author":"Rook","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib107","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2006.08.067","article-title":"Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sezary syndrome","volume":"56","author":"Querfeld","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib108","first-page":"504","article-title":"A\u00a0case of cutaneous T cell lymphoma treated with recombinant interleukin 2 (rIL-2)","volume":"68","author":"Nagatani","year":"1988","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib109","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2133.1992.tb14832.x","article-title":"Successful interleukin-2 therapy of advanced cutaneous T-cell lymphoma","volume":"127","author":"Rybojad","year":"1992","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib110","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/archderm.1995.01690170076011","article-title":"High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma","volume":"131","author":"Marolleau","year":"1995","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib111","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/archderm.1997.03890410120021","article-title":"Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2","volume":"133","author":"Baccard","year":"1997","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.det.2015.05.012_bib112","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V83.8.2081.2081","article-title":"Interleukin-2 treatment in lymphoma: a phase II multicenter study","volume":"83","author":"Gisselbrecht","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib113","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4049\/jimmunol.154.3.1491","article-title":"IL-12 reverses cytokine and immune abnormalities in Sezary syndrome","volume":"154","author":"Rook","year":"1995","journal-title":"J\u00a0Immunol"},{"issue":"9","key":"10.1016\/j.det.2015.05.012_bib114","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2002-01-0231","article-title":"Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines","volume":"100","author":"Wysocka","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/1523-1747.ep12611877","article-title":"Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells","volume":"99","author":"Vowels","year":"1992","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib116","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/1523-1747.ep12330869","article-title":"Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA","volume":"107","author":"Asadullah","year":"1996","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib117","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.012_bib118","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.2001.tb03721.x","article-title":"The role for interleukin-12 therapy of cutaneous T cell lymphoma","volume":"941","author":"Rook","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib119","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","article-title":"A\u00a0phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides","volume":"55","author":"Duvic","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib120","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0026-895X(25)14854-2","article-title":"Purine nucleoside phosphorylase: kinetics, mechanism, and specificity","volume":"3","author":"Krenitsky","year":"1967","journal-title":"Mol Pharmacol"},{"issue":"6 Suppl 5","key":"10.1016\/j.det.2015.05.012_bib121","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1053\/j.seminoncol.2007.11.003","article-title":"Pharmacology and mechanism of action of forodesine, a T-cell targeted agent","volume":"34","author":"Gandhi","year":"2007","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.det.2015.05.012_bib122","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1073\/pnas.071050798","article-title":"Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes","volume":"98","author":"Kicska","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6 Suppl 5","key":"10.1016\/j.det.2015.05.012_bib123","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1053\/j.seminoncol.2007.11.006","article-title":"Mycosis fungoides: pathophysiology and emerging therapies","volume":"34","author":"Duvic","year":"2007","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib124","first-page":"243","article-title":"Purine nucleoside phosphorylase inhibitors in T-cell malignancies","volume":"7","author":"Bantia","year":"2004","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib125","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1567-5769(01)00056-X","article-title":"Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)\u2013a novel potent and orally active immunosuppressive agent","volume":"1","author":"Bantia","year":"2001","journal-title":"Int Immunopharmacol"},{"issue":"13","key":"10.1016\/j.det.2015.05.012_bib126","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2005-03-1309","article-title":"A\u00a0proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)","volume":"106","author":"Gandhi","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.det.2015.05.012_bib127","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11532190-000000000-00000","article-title":"Current and emerging treatment strategies for cutaneous T-cell lymphoma","volume":"70","author":"Lansigan","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.det.2015.05.012_bib128","unstructured":"Duvic M, Forero-Torres A, Foss F, et\u00a0al. Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I\/II Study. ASH Annual Meeting Abstracts. 2006;108(11):2467. November 1, 2006."},{"issue":"9","key":"10.1016\/j.det.2015.05.012_bib129","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdu231","article-title":"Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome)","volume":"25","author":"Dummer","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib130","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1074\/jbc.M511607200","article-title":"Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death","volume":"281","author":"Fernandez","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"11","key":"10.1016\/j.det.2015.05.012_bib131","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib132","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00109-003-0422-2","article-title":"Proteasome inhibition: a new anti-inflammatory strategy","volume":"81","author":"Elliott","year":"2003","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"27","key":"10.1016\/j.det.2015.05.012_bib133","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.012_bib134","series-title":"The complete library of NCCN oncology practice guidelines","author":"National Comprehensive Cancer Network (U.S.)","year":"2000"},{"issue":"10","key":"10.1016\/j.det.2015.05.012_bib135","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.det.2015.05.012_bib136","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","article-title":"EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma","volume":"11","author":"Wilson","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.det.2015.05.012_bib137","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib138","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/07357900600814490","article-title":"Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"24","author":"Mey","year":"2006","journal-title":"Cancer Invest"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib139","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib140","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2013an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.det.2015.05.012_bib141","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/cncr.20587","article-title":"Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)","volume":"101","author":"Crump","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib142","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12032-012-0351-4","article-title":"Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma","volume":"30","author":"Dong","year":"2013","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib143","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","article-title":"GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a phase II study","volume":"80","author":"Lopez","year":"2008","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib144","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.det.2015.05.012_bib145","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1988.6.7.1177","article-title":"Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up","volume":"6","author":"Hallahan","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.det.2015.05.012_bib146","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib147","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2340\/00015555595963","article-title":"Tumour stage of mycosis fungoides treated with bleomycin and methotrexate: report from the Scandinavian mycosis fungoides study group","volume":"59","author":"Groth","year":"1979","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib148","first-page":"647","article-title":"Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study","volume":"63","author":"Grozea","year":"1979","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib149","first-page":"701","article-title":"Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group","volume":"63","author":"Lamberg","year":"1979","journal-title":"Cancer Treat Rep"},{"issue":"5\u20136","key":"10.1016\/j.det.2015.05.012_bib150","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428199809057618","article-title":"Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP","volume":"31","author":"Fierro","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib151","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2340\/0001555560542544","article-title":"Combination chemotherapy in the tumour stage of mycosis fungoides with cyclophosphamide, vincristine, vp-16, adriamycin and prednisolone (cop, chop, cavop): a report from the Scandinavian mycosis fungoides study group","volume":"60","author":"Molin","year":"1980","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib152","first-page":"187","article-title":"Combination chemotherapy for advanced squamous cell carcinoma of the head and neck","volume":"64","author":"Raafat","year":"1980","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"10.1016\/j.det.2015.05.012_bib153","doi-asserted-by":"crossref","first-page":"534","DOI":"10.7326\/0003-4819-83-4-534","article-title":"Cutaneous T-cell lymphomas: the Sezary syndrome, mycosis fungoides, and related disorders","volume":"83","author":"Lutzner","year":"1975","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.det.2015.05.012_bib154","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hon.2900040110","article-title":"Staging and treatment with cyclophosphamide, vincristine and prednisone (CVP) in advanced cutaneous T-cell lymphomas","volume":"4","author":"Tirelli","year":"1986","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2133.1982.tb00332.x","article-title":"Cutaneous T-cell lymphoma: clinicopathological relationships, therapy and survival in ninety-two patients","volume":"107","author":"Hamminga","year":"1982","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib156","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2340\/0001555567179182","article-title":"Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group","volume":"67","author":"Molin","year":"1987","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.det.2015.05.012_bib157","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2340\/0001555567433437","article-title":"Combination chemotherapy with bleomycin, cyclophosphamide, prednisone and etretinate (BCPE) in advanced mycosis fungoides: a six-year experience","volume":"67","author":"Zachariae","year":"1987","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.det.2015.05.012_bib158","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2340\/0001555562162164","article-title":"Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone and transfer factor in mycosis fungoides","volume":"62","author":"Zachariae","year":"1982","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.det.2015.05.012_bib159","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.det.2015.05.012_bib160","first-page":"538","article-title":"Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine","volume":"69","author":"Doberauer","year":"1989","journal-title":"Acta Derm Venereol"},{"issue":"26","key":"10.1016\/j.det.2015.05.012_bib161","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A\u00a0randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"1 Pt 1","key":"10.1016\/j.det.2015.05.012_bib162","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0190-9622(87)70004-8","article-title":"Combined total body electron beam irradiation and chemotherapy for mycosis fungoides","volume":"16","author":"Braverman","year":"1987","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2015.05.012_bib163","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/1097-0142(19861215)58:12<2611::AID-CNCR2820581210>3.0.CO;2-W","article-title":"Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM-M)","volume":"58","author":"Zakem","year":"1986","journal-title":"Cancer"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T01:37:07Z","timestamp":1748569027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":163,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0733863515000571"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.05.012","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}